XERS logo

Xeris Biopharma Holdings (XERS) Cash From Investing

Annual CFI

$4.88 M
+$10.89 M+181.33%

December 1, 2024

Summary

Performance

1-Year Change

+181.33%

3-Year Change

-95.02%

5-Year Change

+304.91%

15-Year Change

+797.57%

XERS Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

76.81%
XERS annual cash flow from investing activities is higher than 76.81% of companies in Healthcare sector

High & Low

All-time High

$97.96 M
XERS annual cash flow from investing activities is currently -95.02% below its historical high of $97.96 million

3-Year Low

-$6.00 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2024
XERS previous annual earnings announcement was published on Dec 1, 2024

Next Annual Earnings Report Date

N/A
XERS next annual earnings announcement has not yet been scheduled

OtherXERScash flowmetrics:

Annual CFF

$36.17 M
XERS annual cash flow from financing activities is $36.17 million

Annual CFO

-$36.98 M
XERS annual cash flow from operations is -$36.98 million

Annual FCF

-$37.85 M
XERS annual free cash flow is -$37.85 million

Annual CAPEX

$868.00 K
XERS annual capital expenditures is $868.00 thousand

Quarterly CFI

$10.02 M
+$102.00 K+1.03%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

-31.65%

5-Year Change

-31.65%

XERS Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

81.94%
XERS quarterly cash flow from investing activities is higher than 81.94% of companies in Healthcare sector

High & Low

All-time High

$36.60 M
XERS quarterly cash flow from investing activities is currently -72.64% below its historical high of $36.60 million

3-Year Low

-$43.98 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
XERS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 9, 2025
XERS next earnings announcement is scheduled for May 9, 2025

OtherXERScash flowmetrics:

Quarterly CFF

$398.00 K
XERS quarterly cash flow from financing activities is $398.00 thousand

Quarterly CFO

$1.98 M
XERS quarterly cash flow from operations is $1.98 million

Quarterly FCF

$1.75 M
XERS quarterly free cash flow is $1.75 million

Quarterly CAPEX

$220.00 K
XERS quarterly capital expenditures is $220.00 thousand

TTM CFI

$4.88 M
-$4.85 M-49.84%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+141.72%

5-Year Change

+141.72%

XERS TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

77.51%
XERS TTM cash flow from investing activities is higher than 77.51% of companies in Healthcare sector

High & Low

All-time High

$97.96 M
XERS TTM cash flow from investing activities is currently -95.02% below its historical high of $97.96 million

3-Year Low

-$19.65 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
XERS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 9, 2025
XERS next earnings announcement is scheduled for May 9, 2025

OtherXERScash flowmetrics:

TTM CFF

$36.17 M
XERS TTM cash flow from financing activities is $36.17 million

TTM CFO

-$36.98 M
XERS TTM cash flow from operations is -$36.98 million

TTM FCF

-$37.85 M
XERS TTM free cash flow is -$37.85 million

TTM CAPEX

$868.00 K
XERS TTM capital expenditures is $868.00 thousand

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

XERS Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+181.3%0.0%0.0%
3 y3 years-95.0%-31.6%+141.7%
5 y5 years+304.9%-31.6%+141.7%

XERS Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-95.0%+181.3%-72.6%+122.8%-95.0%+124.8%
5 y5-year-95.0%+117.8%-72.6%+116.5%-95.0%+111.2%
alltimeall time-95.0%+107.2%-72.6%+116.5%-95.0%+105.6%

Xeris Biopharma Holdings Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
-
$10.02 M(+1.0%)
$4.88 M(-49.8%)
Dec 2024
$4.88 M(-181.3%)
-
-
Sep 2024
-
$9.91 M(+115.4%)
$9.73 M(-32.8%)
Jun 2024
-
$4.60 M(-123.4%)
$14.48 M(-21.0%)
Mar 2024
-
-$19.65 M(-232.2%)
$18.32 M(-405.2%)
Dec 2023
-$6.00 M(-117.4%)
$14.87 M(+1.5%)
-$6.00 M(-48.7%)
Sep 2023
-
$14.65 M(+73.4%)
-$11.70 M(-40.4%)
Jun 2023
-
$8.45 M(-119.2%)
-$19.65 M(+21.0%)
Mar 2023
-
-$43.98 M(-579.7%)
-$16.23 M(-147.1%)
Dec 2022
$34.46 M(-64.8%)
$9.17 M(+36.7%)
$34.46 M(-44.3%)
Sep 2022
-
$6.71 M(-43.5%)
$61.90 M(-16.0%)
Jun 2022
-
$11.87 M(+76.7%)
$73.69 M(-6.0%)
Mar 2022
-
$6.72 M(-81.7%)
$78.38 M(-20.0%)
Dec 2021
$97.96 M(-457.5%)
$36.60 M(+97.8%)
$97.96 M(+42.8%)
Sep 2021
-
$18.50 M(+11.8%)
$68.61 M(-749.2%)
Jun 2021
-
$16.56 M(-37.1%)
-$10.57 M(+8.1%)
Mar 2021
-
$26.30 M(+262.8%)
-$9.78 M(-64.3%)
DateAnnualQuarterlyTTM
Dec 2020
-$27.41 M(+1050.0%)
$7.25 M(-111.9%)
-$27.41 M(-37.3%)
Sep 2020
-
-$60.67 M(-449.8%)
-$43.70 M(-401.7%)
Jun 2020
-
$17.34 M(+99.9%)
$14.48 M(-42.1%)
Mar 2020
-
$8.68 M(-196.0%)
$25.02 M(-1149.9%)
Dec 2019
-$2.38 M(-96.5%)
-$9.04 M(+262.2%)
-$2.38 M(-53.0%)
Sep 2019
-
-$2.50 M(-109.0%)
-$5.07 M(-91.4%)
Jun 2019
-
$27.88 M(-248.9%)
-$58.62 M(-32.4%)
Mar 2019
-
-$18.73 M(+59.7%)
-$86.65 M(+26.9%)
Dec 2018
-$68.26 M(+9651.6%)
-$11.72 M(-79.1%)
-$68.26 M(+20.2%)
Sep 2018
-
-$56.05 M(>+9900.0%)
-$56.77 M(+7469.9%)
Jun 2018
-
-$156.00 K(-53.2%)
-$750.00 K(+8.5%)
Mar 2018
-
-$333.00 K(+41.1%)
-$691.00 K(-1.3%)
Dec 2017
-$700.00 K(+1900.0%)
-$236.00 K(+844.0%)
-$700.00 K(+50.9%)
Sep 2017
-
-$25.00 K(-74.2%)
-$464.00 K(+5.7%)
Jun 2017
-
-$97.00 K(-71.6%)
-$439.00 K(+28.4%)
Mar 2017
-
-$342.00 K
-$342.00 K
Dec 2016
-$35.00 K
-
-

FAQ

  • What is Xeris Biopharma Holdings annual cash flow from investing activities?
  • What is the all time high annual CFI for Xeris Biopharma Holdings?
  • What is Xeris Biopharma Holdings annual CFI year-on-year change?
  • What is Xeris Biopharma Holdings quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Xeris Biopharma Holdings?
  • What is Xeris Biopharma Holdings quarterly CFI year-on-year change?
  • What is Xeris Biopharma Holdings TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Xeris Biopharma Holdings?
  • What is Xeris Biopharma Holdings TTM CFI year-on-year change?

What is Xeris Biopharma Holdings annual cash flow from investing activities?

The current annual CFI of XERS is $4.88 M

What is the all time high annual CFI for Xeris Biopharma Holdings?

Xeris Biopharma Holdings all-time high annual cash flow from investing activities is $97.96 M

What is Xeris Biopharma Holdings annual CFI year-on-year change?

Over the past year, XERS annual cash flow from investing activities has changed by +$10.89 M (+181.33%)

What is Xeris Biopharma Holdings quarterly cash flow from investing activities?

The current quarterly CFI of XERS is $10.02 M

What is the all time high quarterly CFI for Xeris Biopharma Holdings?

Xeris Biopharma Holdings all-time high quarterly cash flow from investing activities is $36.60 M

What is Xeris Biopharma Holdings quarterly CFI year-on-year change?

Over the past year, XERS quarterly cash flow from investing activities has changed by $0.00 (0.00%)

What is Xeris Biopharma Holdings TTM cash flow from investing activities?

The current TTM CFI of XERS is $4.88 M

What is the all time high TTM CFI for Xeris Biopharma Holdings?

Xeris Biopharma Holdings all-time high TTM cash flow from investing activities is $97.96 M

What is Xeris Biopharma Holdings TTM CFI year-on-year change?

Over the past year, XERS TTM cash flow from investing activities has changed by $0.00 (0.00%)